PRODUCT TYPES – Page 21

Biologic hold-time failure for bulk drug substance during tech transfer to a CMO: single-use systems risk controls, leachables review, and supplier oversight actions

When a biologic hold-time failure occurs, the symptoms can emerge at various stages in the production process. Early detection is critical. Here are some common signals you might observe:Click to…

Stability degradation during inspection readiness: GMP investigation and containment strategy

Recognizing symptoms of stability degradation early is crucial for effective containment and risk mitigation. Common signals may include:Click to read the full article.

Biologic leachables signal from single-use systems during PPQ / process validation: how to document root cause when multiple unit operations are involved

Symptoms indicating potential biologic leachables from single-use systems might manifest in various ways throughout the manufacturing process. Common indicators include:Click to read the full article.

Potency variability after cleaning cycle change: CAPA aligned to regulatory expectations

The first step in responding to potency variability issues is recognizing the symptoms or signals that indicate a potential problem. Some common indicators on the manufacturing floor or in the…

Biologic upstream yield drop (OOT) during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms or signals is a critical first step in addressing any production deviation. In the case of a biologic upstream yield drop, tracking various parameters helps in painting a…

Blend uniformity OOS after cleaning cycle change: facility and HVAC risk mitigation

Identifying symptoms early is crucial for mitigating potential risks and maintaining compliance. When dealing with blend uniformity OOS post a cleaning cycle change, the initial signals can include:Click to read…

Biologic endotoxin OOS during deviation investigation board review: patient safety impact assessment and batch disposition governance

Identifying the initial symptoms or signals that indicate a potential endotoxin OOS result is critical for a timely and effective investigation. The following are common signs to monitor:Click to read…

Carryover contamination risk during inspection readiness: CAPA aligned to regulatory expectations

Identifying the symptoms or signals of carryover contamination is critical to initiating an effective investigation. Symptoms typically manifest during various stages of manufacturing, quality control (QC), and testing. Common signals…

Biologic leachables signal from single-use systems after upstream media/raw material change: viral safety and contamination response plan with inspection-ready evidence

When issues related to biologic leachables arise, it's crucial to identify early symptoms or signals as they can be indicative of underlying problems with single-use systems or the materials involved…

Blend uniformity OOS in hormonal manufacturing: facility and HVAC risk mitigation

Symptoms of blend uniformity failures may not be immediately apparent but can manifest in various forms, such as:Click to read the full article.

Biologic sterility assurance gap during CPV trending review: how to document root cause when multiple unit operations are involved

The first step in addressing a biologic sterility assurance gap is recognizing the symptoms or signals that might indicate a problem. These signals may arise from various operational areas, including…

Carryover contamination risk during CPV review: GMP investigation and containment strategy

Understanding the symptoms of carryover contamination during CPV review is critical for timely intervention. Some common signals include:Click to read the full article.